Aboujaoude E Barry JJ Gamel N Memantine augmentation in treatment-resistant obsessive&#8211;compulsive disorder: an open-label trial J Clin Psychopharmacol 2009 29 51-55 
Abramowitz JS Taylor S McKay D Obsessive&#8211;compulsive disorder Lancet 2009 374 491-499 
Amiel JM Mathew SJ Glutamate and anxiety disorders Curr Psychiatry Rep 2007 9 278-283 
Anthony EW Nevins ME Anxiolytic-like effects of N-methyl- Eur J Pharmacol 1993 250 317-324 
Boyce-Rustay JM Holmes A Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice Neuropsychopharmacology 2006 31 2405-2414 
Campeau S Miserendino MJ Davis M Intra-amygdala infusion of the N-methyl- Behav Neurosci 1992 106 569-574 
Coric V Taskiran S Pittenger C Wasylink S Mathalon DH Valentine G Saksa J Wu YT Gueorguieva R Sanacora G Malison RT Krystal JH Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial Biol Psychiatry 2005 58 424-428 
Dunn RW Corbett R Fielding S Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze Eur J Pharmacol 1989 169 1-10 
Emmett MR Mick SJ Cler JA Rao TS Iyengar S Wood PL Actions of Neuropharmacology 1991 30 1167-1171 
Fendt M Koch M Schnitzler HU NMDA receptors in the pontine brainstem are necessary for fear potentiation of the startle response Eur J Pharmacol 1996 318 1-6 
Feusner JD Kerwin L Saxena S Bystritsky A Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial Psychopharmacol Bull 2009 42 81-93 
Heresco-Levy U Kremer I Javitt DC Goichman R Reshef A Blanaru M Cohen T Pilot-controlled trial of Int J Neuropsychopharmacol 2002 5 301-307 
Ho YJ Hsu LS Wang CF Hsu WY Lai TJ Hsu CC Tsai YF Behavioral effects of Brain Res 2005 1043 179-185 
Hood WF Compton RP Monahan JB Neurosci Lett 1989 98 91-95 
Johnson JW Ascher P Glycine potentiates the NMDA response in cultured mouse brain neurons Nature 1987 325 529-531 
Kalueff A Nutt DJ Role of GABA in memory and anxiety Depress Anxiety 1996 4 100-110 
Karcz-Kubicha M Jessa M Nazar M Pla&#378;nik A Hartmann S Parsons CG Danysz W Anxiolytic activity of glycine-B antagonists and partial agonists&#8211;no relation to intrinsic activity in the patch clamp Neuropharmacology 1997 36 1355-1367 
Kessler M Terramani T Lynch G Baudry M A glycine site associated with N-methyl- J Neurochem 1989 52 1319-1328 
Kew JN Kemp JA Ionotropic and metabotropic glutamate receptor structure and pharmacology Psychopharmacology (Berl) 2005 179 4-29 
Kleckner NW Dingledine R Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes Science 1988 241 835-837 
Kleckner NW Dingledine R Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on N-methyl- Mol Pharmacol 1989 36 430-436 
K&#322;odzi&#324;ska A Chojnacka-W&#243;jcik E Anticonflict effect of the glycineB receptor partial agonist, Psychopharmacology (Berl) 2000 152 224-228 
Kotli&#324;ska J Liljequist S A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701, 324 Psychopharmacology (Berl) 1998 135 175-181 
Krystal JH D&#8217;Souza DC Petrakis IL Belger A Berman RM Charney DS Abi-Saab W Madonick S NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders Harv Rev Psychiatry 1999 7 125-143 
Lipman JJ Spencer PS Rapid intracerebroventricular injection assisted by an automatic syringe J Pharmacol Methods 1980 4 327-333 
Lister RG The use of a plus-maze to measure anxiety in the mouse Psychopharmacology (Berl) 1987 92 180-185 
Lydiard RB The role of GABA in anxiety disorders J Clin Psychiatry 2003 64 Suppl 3 21-27 
Mathew SJ Amiel JM Coplan JD Fitterling HA Sackeim HA Gorman JM Open-label trial of riluzole in generalized anxiety disorder Am J Psychiatry 2005 162 2379-2381 
Nemeroff CB The role of GABA in the pathophysiology and treatment of anxiety disorders Psychopharmacol Bull 2003 37 133-146 
Nutt DJ Malizia AL New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder Br J Psychiatry 2001 179 390-396 
Parsons CG Danysz W Quack G Glutamate in CNS disorders as a target for drug development: an update Drug News Perspect 1998 11 523-569 
Pellow S Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid? Methods Find Exp Clin Pharmacol 1986 8 557-565 
Pellow S Chopin P File SE Briley M Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat J Neurosci Methods 1985 14 149-167 
P&#322;a&#378;nik A Pa&#322;ejko W Nazar M Jessa M Effects of antagonists at the NMDA receptor complex in two models of anxiety Eur Neuropsychopharmacol 1994 4 503-512 
Poleszak E Szewczyk B K&#281;dzierska E Wla&#378; P Pilc A Nowak G Antidepressant- and anxiolytic-like activity of magnesium in mice Pharmacol Biochem Behav 2004 78 7-12 
Poleszak E Wla&#378; P Wr&#243;bel A Fidecka S Nowak G NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice Pharmacol Rep 2008 60 655-663 
Przegali&#324;ski E Tatarczy&#324;ska E Chojnacka-W&#243;jcik E Anxiolytic- and antidepressant-like effects of an antagonist at glycineB receptors Pol J Pharmacol 1998 50 349-354 
Przegali&#324;ski E Tatarczy&#324;ska E Chojnacka-W&#243;jcik E The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats Neuropharmacology 2000 39 1858-1864 
Ressler KJ Rothbaum BO Tannenbaum L Anderson P Graap K Zimand E Hodges L Davis M Cognitive enhancers as adjuncts to psychotherapy: use of Arch Gen Psychiatry 2004 61 1136-1144 
Sharma AC Kulkarni SK Evidence for benzodiazepine receptor interaction with MK 801 in anxiety related behaviour in rats Indian J Exp Biol 1993 31 191-193 
Sieghart W Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes Pharmacol Rev 1995 47 181-234 
Sieghart W Fuchs K Tretter V Ebert V Jechlinger M Hoger H Adamiker D Structure and subunit composition of GABAA receptors Neurochem Int 1999 34 379-385 
Stahl SM Don&#8217;t ask, don&#8217;t tell, but benzodiazepines are still the leading treatments for anxiety disorder J Clin Psychiatry 2002 63 756-757 
Tricklebank MD Singh L Oles RJ Preston C Iversen SD The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor Eur J Pharmacol 1989 167 127-135 
Trullas R Jackson B Skolnick P Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors Pharmacol Biochem Behav 1989 34 313-316 
Trullas R Folio T Young A Miller R Boje K Skolnick P Eur J Pharmacol 1991 203 379-385 
Uhlenhuth EH Balter MB Ban TA Yang K International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders J Clin Psychopharmacol 1999 19 23S-29S 
Watson GB Bolanowski MA Baganoff MP Deppeler CL Lanthorn TH Brain Res 1990 510 158-160 
Willetts J Balster RL Leander JD The behavioral pharmacology of NMDA receptor antagonists Trends Pharmacol Sci 1990 11 423-428 
Wood PL Emmett MR Rao TS Mick S Cler J Iyengar S In vivo modulation of the N-methyl- J Neurochem 1989 53 979-981 
Wood PL Hawkinson JE Goodnough DB Formation of J Neurochem 1996 67 1485-1490 
